Elsevier

Nitric Oxide

Volume 97, 1 April 2020, Pages 48-56
Nitric Oxide

Head-to-head comparison of inorganic nitrate and metformin in a mouse model of cardiometabolic disease

https://doi.org/10.1016/j.niox.2020.01.013Get rights and content
Under a Creative Commons license
open access

Highlights

What is already known:

  • Reduced nitric oxide (NO) bioavailability is associated with cardiometabolic dysregulation.

  • Inorganic nitrate and metformin treatments have been associated with AMPK activation and favourable metabolic effects.

What this study adds:

  • The metabolic effects of nitrate were as potent as those observed with metformin

  • Nitrate was superior regarding cardiovascular protection, which may be explained by attenuated oxidative stress

Clinical significance:

  • These findings may have implications for novel nutrition-based strategies against metabolic syndrome, type 2 diabetes and associated complications

Abstract

Background/Purpose

Unhealthy dietary habits contribute to the increasing incidence of metabolic syndrome and type 2 diabetes (T2D), which is accompanied by oxidative stress, compromised nitric oxide (NO) bioavailability and increased cardiovascular risk. Apart from lifestyle changes, biguanides such as metformin are the first-line pharmacological treatment for T2D. Favourable cardiometabolic effects have been demonstrated following dietary nitrate supplementation to boost the nitrate-nitrite-NO pathway. Here we aim to compare the therapeutic value of inorganic nitrate and metformin alone and their combination in a model of cardiometabolic disease.

Experimental approach

Mice were fed control or high fat diet (HFD) for 7 weeks in combination with the NO synthase (NOS) inhibitor l-NAME to induce metabolic syndrome. Simultaneously, the mice were treated with vehicle, inorganic nitrate, metformin or a combination of nitrate and metformin in (drinking water). Cardiometabolic functions were assessed in vivo and tissues were collected/processed for analyses.

Key results

HFD + L-NAME was associated with cardiometabolic dysfunction, compared with controls, as evident from elevated blood pressure, endothelial dysfunction, impaired insulin sensitivity and compromised glucose clearance as well as liver steatosis. Both nitrate and metformin improved insulin/glucose homeostasis, whereas only nitrate had favourable effects on cardiovascular function and steatosis. Mechanistically, metformin and nitrate improved AMPK signalling, whereas only nitrate attenuated oxidative stress. Combination of nitrate and metformin reduced HbA1c and trended to further increase AMPK activation.

Conclusion/Implications

Nitrate and metformin had equipotent metabolic effects, while nitrate was superior regarding protection against cardiovascular dysfunction and liver steatosis. If reproduced in future clinical trials, these findings may have implications for novel nutrition-based strategies against metabolic syndrome, T2D and associated complications.

Cited by (0)

1

Senior authors contributed equally to this work.